Clinical

It may be possible to modify some lifestyle and environmental factors to reduce the risk of patients transitioning from psoriasis to psoriatic arthritis.

Dulaglutide reduces liver fat content in patients with type 2 diabetes (T2D) and nonalcoholic fatty liver disease, when used in combination with standard T2D treatment.

Results from the second major renal outcomes trial for an SGLT2 inhibitor affirm the role of the class in preventing renal decline and kidney failure.

The PARALLAX study points to potential benefits from sacubitril/valsartan in heart failure with preserved ejection fraction, which has no approved treatments.

It's very important to take the EMPEROR-Reduced and DAPA-HF trials together as being complementary, said Milton Packer, MD, of Baylor University Medical Center in Dallas and University of Texas Southwestern Medical School.

A new study shows that empagliflozin, the diabetes drug that set off a market frenzy 5 years ago, is on par with dapagliflozin for certain heart failure patients.

Researchers discuss the case of a 32-year-old patient who is being treated with ruxolitinib over a period of years to treat steroid refractory graft-versus-host disease.

The report explored the use of intravenous lidocaine in a hospital that expanded its use beyond postoperative gastrointestinal surgery.

NCCN added tafasitamab plus lenalidomide to their oncology practice guidelines for patients with relapsed or refractory DLBCL not otherwise specified.

Most people with systemic lupus erythematosus and inflammatory arthritis, who use medications that make them immunosuppressed, are not necessarily at greater risk of hospitalization from coronavirus disease 2019 (COVID-19), according to 2 studies.

A Boxed Warning on increased risk of leg and foot amputations has been removed from the label of canagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor.

A Dutch study shows how genetic testing can help couples avoid passing devastating kidney diseases to their children, but it raises issues of disparities.

Patients who are diagnosed with Waldenström macroglobulinemia (WM) at age 55 or younger tend to have low risk profiles and very high overall survival rates.